comprehensive -WSS

comprehensive

author：comprehensive 2025-08-12 09:09:05 - browse：33

Principal Deputy FDA Commissioner Janet Woodcock Stefani Reynolds/The New York Times via AP

WASHINGTON — Principal Deputy FDA Commissioner Janet Woodcock will retire early next year from the Food and Drug Administration after helping steer the agency through an historic period of medical advances during nearly four decades in key leadership positions, she confirmed to STAT Thursday.

Woodcock, a doctor with a chemistry degree, joined FDA in 1986 at its biologics center, where she oversaw the approval of the first biotechnology-based treatments for multiple sclerosis and cystic fibrosis. In 1994, she was named director of the drug center, where she played a key role in guiding some of the most impactful changes to the regulation of medicine, according to Trump administration FDA Commissioner Scott Gottlieb.

Woodcock envisioned that antibody drugs would become a backbone of therapy and created a more predictable regulatory path for their review and approval, Gottlieb said. She presided over a major expansion and modernization of the generic drug program, standardizing reviews in a way that allowed the industry to become safer and more robust, and crafted the reform of over-the-counter drug reviews.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： Researchers separate signal from noise in heart wearable data

WSS

Seattle police shoot person suspected in downtown stabbing

Couple fighting to bring baby home from Mexico are finally reunited

Chinese researcher claims birth of first gene

Trump got a 'target letter.' What is one and what does it mean?

Biotech investment managers search for lucrative opportunities

Texas board proposes rules on abortion law emergency exemption

leisure time

comprehensive

explore

Heart attack and stroke risk calculators need revising

'Patient friction coefficient' can gauge a clinical trial's patient burden

Hollywood unions extend contract negotiations for actors

Stanford updates investigation of president’s past research

Dobbs anniversary: the lost opportunity of abortion as health care

Suspected Gilgo Beach killer appeared 'traumatized' after arrest: Defense attorney

United colonoscopy coverage change 'may cost lives,' doctors say

Pregnancy ages women, but effects reverse after delivery

As demand for Covid shots wanes, Moderna seeks its next success

Trump got a 'target letter.' What is one and what does it mean?

hotspot

Medical experts are missing from AI regulatory conversations

Biotech investment managers search for lucrative opportunities

Asbestos ban is immediate, but health effects will linger for decades

Actors' union, Hollywood studios squabble over which side to blame as strike enters 5th day

No Labels group has 'steep climb,' but third party 'worth trying': Larry Hogan

Actors' union, Hollywood studios squabble over which side to blame as strike enters 5th day

hotspot

knowledge

hotspot

hotspot